Modality
ADC
MOA
TROP-2 ADC
Target
JAK1
Pathway
Epigenetic
T2DNASH
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
Sep 2018
→ Mar 2028
Phase 1Current
NCT06943241
752 pts·NASH
2018-09→2028-03·Active
752 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-091.9y awayInterim· NASH
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Active
Catalysts
Interim
2028-03-09 · 1.9y away
NASH
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06943241 | Phase 1 | NASH | Active | 752 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP |